Emergent BioSolutions (EBS) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Emergent BioSolutions (EBS) has outperformed Indaptus Therapeutics (INDP) over the past year, losing 28.7% versus a loss of 38.8%. Over five years, EBS leads with a -86.1% price change compared with -99.0% for INDP. Emergent BioSolutions is the larger company by market cap ($362.5 million vs $301.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | INDP |
|---|---|---|
| Share price | $7.07 | $2.26 |
| Market cap | $362.50M | $301.13M |
| 1-day change | +1.73% | -12.74% |
| YTD return | -42.80% | -22.34% |
| 1-year return | -28.73% | -38.75% |
| 5-year return | -86.05% | -98.97% |
| Forward P/E | 6.76 | — |
| EPS (TTM) | $-3.40 | $-6.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.06 | $5.96 |
| 52-week low | $4.36 | $0.92 |
| Distance from 52-week high | -49.72% | -62.08% |
| Average volume | 1.16M | 822.38K |
| Shares outstanding | 51.27M | 133.24M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EBS has outperformed INDP by 10.0 percentage points over the past year.
EBS vs INDP FAQ
Which is bigger, Emergent BioSolutions or Indaptus Therapeutics?
Emergent BioSolutions (EBS) is larger, with a market capitalization of $362.50M compared with $301.13M for Indaptus Therapeutics (INDP).
Which stock has performed better over the past year, EBS or INDP?
EBS returned -28.73% over the past 12 months, compared with -38.75% for INDP (price return, excluding dividends). Past performance does not predict future results.
Are Emergent BioSolutions and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.